IntrinsicIntrinsic
← All summaries

Envoy Medical, Inc.

COCHW
Financials & Chart →

Business Summary

Envoy Medical, Inc. is a hearing health company focused on developing innovative medical technologies for the hearing loss spectrum, aiming to improve access, usability, independence, and quality of life for patients by leveraging the ear's natural anatomy . The company's core business model revolves around the development and potential commercialization of fully implanted hearing devices. Revenue is primarily generated from the sale of Esteem FI-AMEI implants and replacement components, with revenue recognized upon notification of product implantation or use in a surgical procedure . The company also sells prepaid Battery replacement options, and revenue from extended warranty plans is recognized ratably over time .

The company's first product, the Esteem FI-AMEI, received FDA approval in 2010 and remains the only FDA-approved fully implanted active hearing implant on the market . Despite approximately 1,000 devices being implanted globally, it failed to gain commercial traction primarily due to its classification as a hearing aid by the Centers for Medicaid and Medicare Services (CMS), rendering it ineligible for coverage . In late 2015, Envoy Medical shifted its focus to the investigational Acclaim CI, a fully implanted cochlear implant that leverages the company's sensor technology . The Acclaim CI received Breakthrough Device Designation from the FDA in 2019 and is designed to address severe-to-profound sensorineural hearing loss not adequately treated by hearing aids . The company believes the Acclaim CI has the potential to disrupt the cochlear implant market, which is currently dominated by three main incumbents: Cochlear Ltd., Advanced Bionics (Sonova), and Med-El . Cochlear Ltd. is noted as the market leader with approximately 65% of global market share and a market capitalization of approximately $12 billion USD as of December 31, 2025 .

For the fiscal year ended December 31, 2025, Envoy Medical reported net revenues of $241 thousand , an increase of $16 thousand or 7.1% compared to $225 thousand in the prior year. Cost of goods sold increased by $132 thousand to $874 thousand in 2025, up from $742 thousand in 2024, primarily due to a $190 thousand increase in scrap and non-recurring expenses, partially offset by a $77 thousand reduction in third-party fees. Research and development expenses rose by $2,307 thousand to $12,486 thousand in 2025 from $10,179 thousand in 2024, reflecting the transition into the clinical trial phase. Sales and marketing expenses decreased by $514 thousand to $1,220 thousand in 2025 from $1,734 thousand in 2024, mainly due to reduced legal fees for securing Esteem FI-AMEI reimbursement . General and administrative expenses increased by $1,105 thousand to $7,931 thousand in 2025 from $6,826 thousand in 2024, driven by a $315 thousand severance accrual for the former CFO and $299 thousand in increased consultant costs. The company reported an operating loss of $22,270 thousand in 2025, compared to $19,256 thousand in 2024. Net loss for 2025 was $23,756 thousand , an increase from $20,795 thousand in 2024. Diluted EPS was $(1.23) in 2025, compared to $(1.49) in 2024. As of December 31, 2025, cash and equivalents stood at $3,739 thousand , down from $5,483 thousand in 2024. Total liabilities were $20,325 thousand in 2025, a decrease from $30,380 thousand in 2024. The company had an accumulated deficit of $313,396 thousand as of December 31, 2025. Net cash used in operating activities was $(18,201) thousand in 2025, compared to $(17,949) thousand in 2024.

During the reported period, Envoy Medical completed enrollment of all 56 patients in its pivotal clinical study for the Acclaim CI on March 10, 2025 . This study is designed to demonstrate the safety and efficacy of the Acclaim CI for severe to profound sensorineural hearing loss . The company also completed a public offering on February 12, 2026, which generated aggregate gross proceeds of approximately $30,000 thousand and net proceeds of approximately $27,730 thousand . These proceeds are intended for working capital and general corporate purposes to fund operations during the Acclaim CI clinical study . Additionally, on August 25, 2025, the company extinguished all outstanding principal and accrued interest on term loans from a related party in exchange for a $100 thousand payment, resulting in a gain on extinguishment of $27,879 thousand recorded as a capital contribution. The expiration date of the associated Term Loan Warrants was extended to December 31, 2028 .

Business Outlook

Envoy Medical anticipates obtaining FDA approval for the Acclaim CI in late 2027 or early 2028, contingent on the FDA's review process and timeline, with potential delays extending to the first half of 2028 if a panel review is requested . The company expects to incur significant and increasing operating losses for the foreseeable future, driven by continued research and development of the Acclaim CI, efforts to secure regulatory and marketing approvals outside the United States, establishment of sales, marketing, and distribution infrastructure, and increased costs associated with operating as a public company .

A major growth area for Envoy Medical is the commercialization of the Acclaim CI, which is designed to address severe-to-profound sensorineural hearing loss not adequately addressed by hearing aids . The company believes there is a significant untapped market of approximately 2.8 million adults in the United States who could qualify for a cochlear implant but choose not to get traditional, partially-implanted devices due to external components . Based on an assumed selling price of $30,000 for a traditional cochlear implant (with the Acclaim CI expected to command a $5,000 premium over current partially-implanted devices), the adult cochlear implant market in the United States alone represents a potential market opportunity of over $80 billion . The annual market opportunity for adult cochlear implants in the United States is estimated to exceed $750 million by 2026, with roughly 25,000 to 30,000 adults implanted annually . The company plans to initially target approximately 30 surgical sites for training and implantation upon commercialization, with an intent to add an additional 30 sites each year until there are roughly 150 active implanting sites .

Another potential growth area is the Esteem FI-AMEI, which could become a viable product if the bipartisan Congressional bill, the Hearing Device Coverage Clarification Act, is successful in clarifying that fully implanted active middle ear hearing devices (FI-AMEIs) are prosthetics and eligible for Medicare and Medicaid coverage . If this reimbursement policy changes, the Esteem FI-AMEI, an existing FDA-approved product, would be ready to capitalize on such a change, although it would benefit from upgrades to its power source and chip design, which are not currently a priority . New implantations of the Esteem FI-AMEI are not expected to exceed a few per year until, and if, the reimbursement policy changes .

Operationally, the company expects its research and development expenses to continue to increase as it initiates clinical trials for the Acclaim CI and prepares for possible commercialization . Sales and marketing expenses are also projected to increase as the company expands its personnel to support growth . General and administrative expenses are expected to rise due to increased administrative personnel, costs of expanding operations, and compliance requirements as a public company . The company anticipates that its expenses will increase significantly if it needs to conduct additional clinical trials or experiences delays in enrollment .

Regarding capital allocation, the company received approximately $27,730 thousand in net proceeds from the February 2026 Offering, which it intends to use for working capital and other general corporate purposes to fund operations during the Acclaim CI clinical study . The potential additional gross proceeds from the full exercise of Series A-1 Warrants and Series A-2 Warrants are approximately $18,000 thousand and $30,000 thousand , respectively, totaling $48,000 thousand . The company currently intends to retain all available funds and future earnings to fund business development and growth, and does not anticipate declaring or paying any cash dividends on Class A Common Stock for the foreseeable future, though it will pay dividends on Series A Preferred Stock .

Risk Factors

Envoy Medical faces substantial risks, including its status as an early-stage company with a history of losses, having incurred net losses of approximately $23.8 million and $20.8 million for the years ended December 31, 2025 and 2024, respectively, and an accumulated deficit of approximately $313.4 million as of December 31, 2025. The company's financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern . The successful commercialization of the Acclaim CI is uncertain and depends on obtaining FDA approval, which is anticipated in late 2027 or early 2028 , but may be delayed. Clinical failure can occur at any stage, and the company's limited clinical experience with the Acclaim CI may not predict future results . The company operates in a highly competitive medical device industry with larger, more diversified competitors like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El , who have greater financial and operational resources . Reimbursement policies are critical, and failure to obtain or maintain adequate coverage and reimbursement levels for the Acclaim CI could severely limit marketability and revenue generation . The company is highly dependent on key members of its executive management team, and their loss could impede business plans and growth strategies . Supply chain disruptions, particularly from single-source suppliers for critical components, could delay production or increase costs . The estimated size and growth of the addressable market for the Acclaim CI may be smaller than anticipated, and the company may not capture projected market share . Furthermore, the company has identified material weaknesses in its internal control over financial reporting, including insufficient accounting personnel and lack of formal risk assessment and accounting policies . The market price of its Class A Common Stock has been and may continue to be extremely volatile, trading as low as $0.36 and as high as $11.46 since the Business Combination, and the company received a Nasdaq staff determination notice for failing to comply with the $1.00 minimum bid price requirement . The exercise of outstanding warrants, including 14,166,666 Public Warrants at an exercise price of $11.50 per share , 1,135,499 Shortfall Warrants at $1.50 per share , and 120,000,000 Series A Warrants at $0.40 per share from the February 2026 Offering, would result in substantial dilution to existing stockholders.

Management Priorities

Management's overall tone emphasizes the company's dedication to providing innovative medical technologies across the hearing loss spectrum, with a primary focus on the investigational Acclaim CI, which they believe has the potential to disrupt the cochlear implant market. They explicitly state their anticipation of obtaining FDA approval for the Acclaim CI in late 2027 or early 2028, acknowledging that this timeline is uncertain and subject to the FDA's review process, with potential delays extending to the first half of 2028 if a panel review is requested . The three strategic priorities emphasized for the period ahead appear to be: first, successfully completing the pivotal clinical study for the Acclaim CI and securing FDA approval; second, establishing distribution channels and strategic relationships with clinics and healthcare professionals to commercialize the Acclaim CI, with an initial target of carefully selecting roughly 30 sites and then adding an additional 30 sites every year until there are approximately 150 active implanting sites ; and third, managing liquidity and capital resources to fund ongoing operations, including the clinical trials, with the recent February 2026 Offering providing approximately $27,730 thousand in net proceeds for working capital and general corporate purposes.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 7, MD&A — Key Components of Our Results of Operations — Revenue
  3. [3] Item 7, MD&A — Key Components of Our Results of Operations — Revenue
  4. [4] Item 1, Business — Overview
  5. [5] Item 1, Business — Overview
  6. [6] Item 1, Business — Overview
  7. [7] Item 1, Business — Overview
  8. [8] Item 1, Business — Acclaim CI — A Breakthrough Device
  9. [9] Item 1, Business — Acclaim CI's Market Opportunity
  10. [10] Item 1, Business — Market Competition
  11. [11] Item 1, Business — Market Competition
  12. [12] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  13. [13] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  14. [14] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  15. [15] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  16. [16] Item 7, MD&A — Results of Operations — Cost of Goods Sold
  17. [17] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  18. [18] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  19. [19] Item 7, MD&A — Results of Operations — Cost of Goods Sold
  20. [20] Item 7, MD&A — Results of Operations — Cost of Goods Sold
  21. [21] Item 7, MD&A — Results of Operations — Research and Development Expenses
  22. [22] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  23. [23] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  24. [24] Item 7, MD&A — Results of Operations — Sales and Marketing Expenses
  25. [25] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  26. [26] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  27. [27] Item 7, MD&A — Results of Operations — Sales and Marketing Expenses
  28. [28] Item 7, MD&A — Results of Operations — General and Administrative Expenses
  29. [29] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  30. [30] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  31. [31] Item 7, MD&A — Results of Operations — General and Administrative Expenses
  32. [32] Item 7, MD&A — Results of Operations — General and Administrative Expenses
  33. [33] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  34. [34] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  35. [35] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  36. [36] Item 7, MD&A — Results of Operations — Comparison of the Years Ended December 31, 2025 and 2024
  37. [37] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  38. [38] Item 8, Consolidated Statements of Operations and Comprehensive Loss
  39. [39] Item 7, MD&A — Liquidity and Capital Resources
  40. [40] Item 7, MD&A — Liquidity and Capital Resources
  41. [41] Item 8, Consolidated Balance Sheets
  42. [42] Item 8, Consolidated Balance Sheets
  43. [43] Item 7, MD&A — Overview
  44. [44] Item 7, MD&A — Cash Flows — Cash Flows Used in Operating Activities
  45. [45] Item 7, MD&A — Cash Flows — Cash Flows Used in Operating Activities
  46. [46] Item 7, MD&A — Recent Developments — Enrollment of Clinical Trial
  47. [47] Item 1, Business — Timeline to Commercialization of Acclaim CI
  48. [48] Item 7, MD&A — Recent Developments — February 2026 Offering
  49. [49] Item 7, MD&A — Recent Developments — February 2026 Offering
  50. [50] Item 7, MD&A — Recent Developments — February 2026 Offering
  51. [51] Item 7, MD&A — Debt Extinguishment and Warrant Extension
  52. [52] Item 7, MD&A — Debt Extinguishment and Warrant Extension
  53. [53] Item 7, MD&A — Debt Extinguishment and Warrant Extension
  54. [54] Item 7, MD&A — Overview
  55. [55] Item 7, MD&A — Overview
  56. [56] Item 1, Business — Acclaim CI's Market Opportunity
  57. [57] Item 1, Business — Acclaim CI's Market Opportunity
  58. [58] Item 1, Business — Acclaim CI's Market Opportunity
  59. [59] Item 1, Business — Acclaim CI's Market Opportunity
  60. [60] Item 1, Business — Acclaim CI's Market Opportunity
  61. [61] Item 1, Business — Acclaim CI's Market Opportunity
  62. [62] Item 1, Business — Go-To-Market Strategy
  63. [63] Item 1, Business — Esteem FI-AMEI — a potentially viable product with reimbursement
  64. [64] Item 1, Business — Esteem FI-AMEI — a potentially viable product with reimbursement
  65. [65] Item 1, Business — Esteem FI-AMEI — a potentially viable product with reimbursement
  66. [66] Item 7, MD&A — Key Components of Our Results of Operations — Research and Development Expenses
  67. [67] Item 7, MD&A — Key Components of Our Results of Operations — Sales and Marketing Expenses
  68. [68] Item 7, MD&A — Key Components of Our Results of Operations — General and Administrative Expenses
  69. [69] Item 7, MD&A — Key Components of Our Results of Operations — Research and Development Expenses
  70. [70] Item 7, MD&A — Recent Developments — February 2026 Offering
  71. [71] Item 7, MD&A — Recent Developments — February 2026 Offering
  72. [72] Item 7, MD&A — Recent Developments — February 2026 Offering
  73. [73] Item 7, MD&A — Recent Developments — February 2026 Offering
  74. [74] Item 7, MD&A — Recent Developments — February 2026 Offering
  75. [75] Item 5, Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
  76. [76] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  77. [77] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  78. [78] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  79. [79] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  80. [80] Item 1, Business — Timeline to Commercialization of Acclaim CI
  81. [81] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  82. [82] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  83. [83] Item 1, Business — Market Competition
  84. [84] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  85. [85] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  86. [86] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  87. [87] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  88. [88] Item 1A, Risk Factors — Risks Relating to Our Business and Operations
  89. [89] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  90. [90] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  91. [91] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  92. [92] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  93. [93] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  94. [94] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  95. [95] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  96. [96] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  97. [97] Item 1A, Risk Factors — Risks Relating to Our Class A Common Stock
  98. [98] Item 7, MD&A — Overview
  99. [99] Item 1, Business — Go-To-Market Strategy
  100. [100] Item 7, MD&A — Recent Developments — February 2026 Offering

Analysis on 5/20/2026